Dalidowicz, M; Howell-Spooner, B. What is the efficacy of a 4th booster dose for COVID-19? 2022 May 27, Document no.: EOC220304v002 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 23 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc493
Miller, L. What is the safety/efficacy of the Novavax vaccine? 2022 Mar 04, Document no.: EOC220302 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 19 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc452
Miller, L., Howell-Spooner, B. How effective are COVID-19 vaccines? 2022 Jan 14, Document no.: INF031801v020 ESR . In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 9 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc425
Miller, L., Howell-Spooner, B. What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population? 2021 Sep 29, Document no.: EOC210902 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 14 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc375
Howell-Spooner, B., Young, C.. What is the evidence for the effectiveness of universal mask use in the pediatric population?? 2021 Sep 28, Document no.: EOC210901 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 25 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc374
Howell-Spooner, B., Mueller, M. What are the effects of the new COVID variants on transmission and school reopenings in pediatric populations? 2021 Aug 18, Document no.: PH030801v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 49 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc359
Young, C; Mueller, M. What are the causes of vaccine hesitancy? What programs/approaches have been successful in reducing vaccine hesitancy? 2021 Aug 11, Document no.: EOC012201v3 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 26 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc355
Miller, L, Howell-Spooner, B. What is known about safety/efficacy of global vaccines not approved in Canada? What are the impacts on international travel and vaccination policies? 2021 Jul 16, Document no.: INF210701 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 24 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc349
Miller, L; Howell-Spooner, B. What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? 2021 Apr 01; Document no.: EOC210302 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc289
Miller, L; Howell-Spooner, B. What are the differences between COVID-19 vaccines and how should they be distributed based on population group(s)? 2021 Mar 11; Document no.: EOC031001-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 11 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc275
Miller, L; Howell-Spooner, B. What are the vaccination strategies for vulnerable populations? 2021 Mar 04; Document no.: PH030401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 33 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc272
Miller, L; Howell-Spooner, B. What is the risk of transmission of COVID-19 from high respiratory efforts for prolonged periods of time (>15 min) at a physical distance of 3-4 m or more? 2021 Jan 27; Document no.: PH012501-02 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 15 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc254
Miller, L; Howell-Spooner, B. What is the risk of transmission of COVID-19 from high respiratory efforts for prolonged periods of time (>15 min) at a physical distance of 3-4 m or more? 2021 Jan 26; Document no.: PH012501-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 29 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc252
Mueller, M.; Young, C. How safe are the Pfizer and Moderna vaccinations? 2021 Jan 21; Document no.: EOC011901-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 31 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc247
Mueller, M; Howell-Spooner, B. How are other jurisdictions distributing COVID-19 vaccines in non-healthcare worker environments and what is the rationale for those distribution models? 2021 Jan 15; Document no.: PH011401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 15 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc240
Miller, L; Fox, L. How is COVID-19 transmitted from person-to-person and what is the most common source of transmission? 2020 Dec 15; Document no.: INF121501-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 16 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc223
Howell-Spooner, B; Young, C. What is the evidence for the effectiveness of universal mask use by the public? 2020 Dec 1; Document no.: EOC062301v3-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 67 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc215
Miller, L; Howell-Spooner, B. What public health interventions are effective in reducing the burden of COVID-19 disease in comparable jurisdictions to Saskatchewan? 2020 Nov 13; Document no.: PH111001-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 25 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc204
Mueller, M; Young, C. What is the evidence surrounding facial mask exemptions for COVID-19? 2020 Sep 14; Document no.: EOC091101-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 19 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc176
Mueller, M; Young, C. Is the use of thermometers an effective screening strategy for students in schools during COVID-19? 2020 Sep 2; Document no.: EOC090201-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 6 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc169
